Multilayered control of retinal stem/progenitor cell fate in the single-cell and organoid era: Developmental blueprints and regenerative opportunities

Table 1 Retinal regenerative lineage library - comparative controllability, scalability, and translational fit

Lineage/source class	Representative product/strategy in manuscript	Primary strengths	Dominant controllability limits	Key safety risks	Best-fit indication stage	Translational role in your framework
Embryonic/developmental RPCs	“Reference progenitors” defining competence windows	Gold-standard developmental program; informs TF/enhancer logic	Not scalable; not a clinical source	Ethical/availability constraints	N/A (instructional)	Blueprint to recreate/bypass competence windows
MG in situ	In vivo reprogramming	Anatomically native; correct laminar position	Competence locked by Notch/NFI/Prox1; prone to reactive reversion	Off-target AAV expression; scarring; uncontrolled proliferation	Early-intermediate, niche-permissive	“Gene-only” regeneration if evidence-standard met
CMZ-like/adult stem cell candidates	Hypothesis-generating reservoirs	May reveal edge-niche triggers	In vivo neurogenesis inconsistent; culture-induced artifacts	Lineage ambiguity	Low priority	Mechanistic inspiration rather than a product source
hPSC-RPE (suspension)	Subretinal injection; RPESC-RPE-4W	Mature monolayer identity; imaging-friendly endpoints	Repolarization on diseased Bruch’s; heterogeneous distribution	Proliferation/tumorigenicity monitoring needed	Intermediate-advanced GA/AMD	Clinically advanced “vanguard” replacement
hPSC-RPE (patch/scaffold)	CPCB-RPE1, sheets/patches	Pre-polarized monolayer; surrogate substrate	Higher surgical burden; complication spectrum	PVR/retinal detachment risk	Advanced structural loss	Durability-first strategy
Photoreceptor precursors	“Goldilocks zone” post-mitotic precursors	Potential for vision restoration via synaptic integration	Integration vs material transfer confound; maturity tuning required	Ectopic differentiation; limited connectivity proof	End-stage vs mid-stage stratification needed	Replace + require rigorous mechanism-of-benefit parsing
Organoid-derived laminated outputs	Engineered scaffolds; ecosystem completion	Tissue-like architecture; testbed for causality + product	Heterogeneity, batch effects; microenvironment missingness	Off-target tissues; stress programs	Preclinical → translational	Programmable developmental proxy + manufacturing challenge

RPCs: Retinal progenitor cells; TF: Transcription factor; N/A: Not applicable; MG: Müller glia; NFI: Nuclear factor I; Prox1: Prospero homeobox 1; AAV: Adeno-associated virus; CMZ: Ciliary marginal zone; hPSC-RPE: Human pluripotent stem cell-derived retinal pigment epithelium; RPESC: Retinal pigment epithelium stem cell; RPESC-RPE-4W: Retinal pigment epithelium stem cell-derived retinal pigment epithelium progeny at 4 weeks of differentiation; GA: Geographic atrophy; AMD: Age-related macular degeneration; CPCB-RPE1: California Project to Cure Blindness-retinal pigment epithelium 1; PVR: Proliferative vitreoretinopathy; RPE: Retinal pigment epithelium.